SNOMED CT Editorial Guide

Search

Versions Compared

Old Version 6

changes.mady.by.user Krista Lilly

Saved on

compared with

New Version 7

changes.mady.by.user Krista Lilly

Saved on

Key

  • This line was added.
  • This line was removed.
  • Formatting was changed.

Overview

CD-precise concepts representing discrete dose form (e.g. tablets, capsules, pessaries, suppositories, sachets, ampules or vials containing solid dose forms such as powders or granules, and metered dose delivery products such as inhalers and spray) are modeled using presentation strength attributes; concentration strength attributes are not allowed for these concepts in the International Release.

For example,

    • Product containing precisely abacavir 300 milligram/1 each conventional release oral tablet (clinical drug)
    • Product containing precisely abacavir 600 milligram and lamivudine 300 milligram/1 each conventional release oral tablet (clinical drug)
    • Product containing precisely afatinib (as afatinib dimaleate) 30 milligram/1 each conventional release oral tablet (clinical drug)
    • Product containing precisely aztreonam 500 milligram/1 vial powder for conventional release solution for injection (clinical drug)
    • Product containing precisely flucloxacillin (as flucloxacillin sodium) 250 milligram/1 vial powder for conventional release solution for injection (clinical drug)
    • Product containing precisely budesonide 200 microgram/1 actuation conventional release powder for inhalation (clinical drug)
Note
titleException

Pre-filled pens or cartridges are discrete dose forms as they can be counted.  In the International edition of SNOMED CT, clinical drugs presenting in pre-filled pens or cartridges are modeled with normalized concentration strength.

Example of pre-filled pen:

    • One pre-filled pen for injection contains 2 mg semaglutide in a 1.5 ml solution
    • FSN: 782102009 |Product containing precisely semaglutide 1.34 milligram/1 milliliter conventional release solution for injection (clinical drug)|

When a product has a metered delivery, the strength is "per actuation" not as a concentration.

For example,

    • 1263426000 |Product containing precisely xylometazoline hydrochloride 140 microgram/1 actuation conventional release nasal spray (clinical drug)|
Warning

Lyophilized dose forms are out of scope for the international edition of SNOMED CT.

Modeling

Stated parent concept

763158003 |Medicinal product (product)

Semantic tag(clinical drug)
Definition status

Defined

  • Exception:
    • Concepts with product strength that is "not equal to" (e.g. with product strength expressed as a range, greater than, or less than) will have a definition status of Primitive.

Attribute:

Has manufactured dose form

Range: <736542009 |Pharmaceutical dose form (dose form)

      • While the allowed range for this attribute is broader, the CD-precise discrete dose form concepts should only use <736542009 |Pharmaceutical dose form (dose form)|, excluding grouper concepts based on intended site (e.g. 740596000 |Cutaneous dose form (dose form)|, 385268001 |Oral dose form (dose form)|)

Cardinality: 1..1

Powder and granules for oral suspension, solution, etc. may be modeled using concentration strength and the administrable dose form (e.g. 1145409004 |Product containing precisely amoxicillin 25 milligram/1 milliliter and clavulanic acid (as clavulanate potassium) 6.25 milligram/1 milliliter conventional release oral suspension (clinical drug)|)

Attribute:

Has unit of presentation

Range:  <732935002 |Unit of presentation (unit of presentation)|

Cardinality: 1..1

Attribute:

Count of base of active ingredient (attribute)

Concrete Type: Integer

Range: >#0..

Cardinality: 1..1

Relationship groupOne relationship group containing one instance of each of the following attributes is required for each precise active ingredient.
  • Has precise active ingredient

Range:  <105590001 |Substance (substance)| excluding concepts representing structural groupers, dispositions, or combined substances

Cardinality: 1..1 per relationship group

Note:

  • The PAI cannot be modeled as a substance hydrate or solvate unless the BoSS is expressed as a hydrate or solvate.
  • Concepts containing pancreatic enzymes are modeled based on the discrete enzymes; because of variability between real clinical drugs, synonyms representing a total amount in a particular product will not be included in the International Release.
  • Has basis of strength substance

Range: <105590001 |Substance (substance)| excluding concepts representing structural groupers, dispositions, or combined substances

Cardinality: 1..1 per relationship group

  • Has presentation strength numerator value 

Concrete Type: Decimal

Range: >#0..

Cardinality: 1..1 per relationship group

  • Has presentation strength numerator unit

Range: <767524001 |Unit of measure (qualifier value)| 

Cardinality: 1..1 per relationship group

  • Has presentation strength denominator value

Concrete Type: Decimal

Range: >#0..

Cardinality: 1..1 per relationship group

For this pattern, the attribute value is 1.

The denominator strength value is required for concepts in the International Release even if the value = 1, because including denominators for only some concepts negatively affects the classification results.

  • Has presentation strength denominator unit
  • Range: <767524001 |Unit of measure (qualifier value)| 
    • While the allowed range for this attribute is broader, the CD-precise concepts representing discrete dose forms should only use <732935002 |Unit of presentation (unit of presentation).
  • Cardinality: 1..1 per relationship group

Naming

FSN

Use one of the following patterns for the FSN.

Where Precise active ingredient = BoSS and Unit of presentation = discrete solid dose form (e.g. capsule, lozenge, pessary, suppository, tablet):

  • Product containing precisely <BoSS FSN> <Presentation strength numerator value FSN> <Presentation strength numerator unit FSN>/<Presentation strength denominator value FSN> each <Manufactured dose form FSN> (clinical drug)

For example,

        • Product containing precisely abacavir 300 milligram/1 each conventional release oral tablet (clinical drug)
        • Product containing precisely abacavir 600 milligram and lamivudine 300 milligram/1 each conventional release oral tablet (clinical drug)
        • Product containing precisely atropine sulfate 600 microgram/1 each conventional release oral tablet (clinical drug)
        • Product containing precisely codeine sulfate 15 milligram/1 each conventional release oral tablet (clinical drug)

Where Precise active ingredient is not = BoSS and Unit of presentation = discrete solid dose form (e.g. capsule, lozenge, pessary, suppository, tablet):

  • Product containing precisely <BoSS FSN> (as <Precise active ingredient FSN>) <Presentation strength numerator value FSN> <Presentation strength numerator unit FSN>/<Presentation strength denominator value FSN> each <Manufactured dose form FSN> (clinical drug)

For example,

        • Product containing precisely doxazosin (as doxazosin mesilate) 4 milligram/1 each conventional release oral tablet (clinical drug)
        • Product containing precisely disopyramide (as disopyramide phosphate) 150 milligram/1 each prolonged-release oral tablet (clinical drug)

Where Precise active ingredient = BoSS and Unit of presentation = other discrete dose form (e.g. actuation, vial, sachet)

  • Product containing precisely <BoSS FSN> <Presentation strength numerator value FSN> <Presentation strength numerator unit FSN>/Presentation strength denominator value FSN> <Presentation strength denominator unit FSN> Manufactured dose form FSN> (clinical drug)

For example,

        • Product containing precisely aztreonam 500 milligram/1 vial powder for conventional release solution for injection (clinical drug)
        • Product containing precisely budesonide 200 microgram/1 actuation conventional release powder for inhalation (clinical drug)

Where Precise active ingredient is not = BoSS and Unit of presentation = other discrete dose form (e.g. actuation, vial, sachet)

  • Product containing precisely <BoSS FSN> (as <Precise active ingredient FSN>) <Presentation strength numerator value FSN> <Presentation strength numerator unit FSN>/<Presentation strength denominator value FSN> <Presentation strength denominator unit FSN> Manufactured dose form FSN> (clinical drug)

For example,

        • Product containing precisely flucloxacillin (as flucloxacillin sodium) 250 milligram/1 vial powder for conventional release solution for injection (clinical drug)
        • Product containing precisely buserelin (as buserelin acetate) 100 microgram/1 actuation conventional release nasal spray (clinical drug)
Preferred Term

Use one of the following patterns for the PT.

Where BoSS = Precise active ingredient:

  • <BoSS PT> <Presentation strength numerator value PT> <Presentation strength numerator unit PT> <Manufactured dose form PT> <Has unit of presentation PT>

For example,

        • Abacavir 300 mg oral tablet
        • Abacavir 600 mg and lamivudine 300 mg oral tablet
        • Atropine sulfate 600 microgram oral tablet
        • Codeine sulfate 15 mg oral tablet
        • Aztreonam 500 mg powder for solution for injection vial
        • Budesonide 200 microgram/actuation powder for inhalation
        • Buserelin (as buserelin acetate) 100 microgram/actuation nasal spray

        • Ivacaftor 25 mg oral granules sachet

Where BoSS is not = Precise active ingredient:

  • <BoSS PT> (as <Precise active ingredient PT>) <Presentation strength numerator value PT> <Presentation strength numerator unit PT> <Manufactured dose form PT> <Has unit of presentation PT>

For example,

        • US PT: Doxazosin (as doxazosin mesylate) 4 mg oral tablet
        • GB PT: Doxazosin (as doxazosin mesylate) 4 mg oral tablet
        • US/GB PT: Disopyramide (as disopyramide phosphate) 150 mg prolonged-release oral tablet
        • US PT: Floxacillin (as floxacillin sodium) 250 mg powder for solution for injection vial
        • GB PT: Flucloxacillin (as flucloxacillin sodium) 250 mg powder for solution for injection vial
Synonyms

Synonyms matching the FSN are not required.

Exemplars

The following illustrates the stated view for 318783003 |Product containing precisely doxazosin (as doxazosin mesilate) 4 milligram/1 each conventional release oral tablet (clinical drug)|:

The following illustrates the inferred view for 318783003 |Product containing precisely doxazosin (as doxazosin mesilate) 4 milligram/1 each conventional release oral tablet (clinical drug)|:

The following illustrates the stated view for 783301004 |Product containing precisely abacavir (as abacavir sulfate) 600 milligram and lamivudine 300 milligram/1 each conventional release oral tablet (clinical drug)|:

The following illustrates the inferred view for 783301004 |Product containing precisely abacavir (as abacavir sulfate) 600 milligram and lamivudine 300 milligram/1 each conventional release oral tablet (clinical drug)|:

Sodium valproate and Valproic acid

When a manufacturer SPC label indicates that two separate ingredients, sodium valproate and valproic acid, are present in the formulation, and thus, one of the substances is a modification of the other, then each ingredient must be modeled separately within its own role group.

Two ungrouped attributes are also required:

  1. |Count of active ingredient| with the total number of active ingredients
  2. |Count of base of active ingredient| with the total number of base active ingredients

For example,

    • The summary of product characteristics for a manufactured product for a sachet of 100 mg sodium valproate prolonged-release granules contains Sodium valproate 66.66 mg and Valproic acid 29.03 mg, that must be separately modeled as |Product containing precisely sodium valproate 66.66 milligram and valproic acid 29.03 milligram/1 sachet prolonged-release oral granules (clinical drug)|